Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Background: Older diabetic people are at greater risk of cognitive decline than non-diabetic people. Vitamin B12 deficiency in older people is associated with cognitive impairment and Alzheimer's disease. Vitamin B12 deficiency may therefore contribute to cognitive decline in older diabetic people.

Objective: To determine whether the correction of mild vitamin B12 deficiency in cognitively normal older diabetic people reduces the incidence of cognitive decline.

Design: randomized, double blind, placebo controlled trial Subject: Cognitively normal diabetic outpatients aged 70 years or older with plasma vitamin B12 150-300 pmol/L in medical and family medicine/ general outpatient clinics.

Procedure: After excluding those with clinical manifestations of vitamin B12 deficiency and without family member who can reliably inform on cognitive functioning (personal contact at least once a week), eligible patients will be invited to participate in this clinical trial. After obtaining written consent, research assistant (RA) will record demographic and clinical information from the subjects and perform neuropsychological tests - 1. Clinical dementia rating scale (CDR), 2. neurocognitive test battery (see below) 3. Chinese Mini mental state examination (MMSE), 4. Geriatric depression scale (GDS). Fasting blood will be taken for serum methylmalonic acid (MMA). Those with cognitive impairment and significant comorbidities will be excluded.

264 eligible subjects will be randomly assigned to take either two Vitamin B12 500 microgram or two identical looking placebo tablets once daily for 27 months.

All subjects or family caregivers are reviewed in the research clinic every 12 weeks in which the research assistant performs a pill count and dispenses the trial tablets. At 9 monthly intervals, the subjects will have neurocognitive test battery repeated at research clinic. CDR will be repeated at month 18 and 27. At month 9 and 27, fasting serum MMA and vitamin B12 will be repeated.


Options:
A: Arm Label: vitamin supplements; Type: EXPERIMENTAL; Interventions: Drug: Folic Acid, Drug: Vitamin B6, Drug: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: folic acid (0.8 mg); Assigned to Arm(s): N/A
C: Arm Label: Vitamin B12; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Vitamin B12 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4

Answer: C